$213 million raised by German coronavirus vaccine developer CureVac in IPO
Image Credit: Shortpedia
German biotechnology firm CureVac has raised $213 million in its initial public offering on Thursday. The drugmaker made its debut in the stock market, selling 13.33 million shares at $16 apiece. The firm's shares will start trading in New York on Friday. CureVac is the first coronavirus vaccine developer to enter the stock market setting the course for its competitors. The firm is working to develop a Covid19 vaccine.